高亲和度的CD8变体通过低亲和度的TCR增强了pMHCI抗原识别的灵敏度
Lea Knezevic1, Tassilo L A Wachsmann2, Ore Francis3
1Faculty of Health Sciences, University of Bristol, Bristol, UK; Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands.
工程 CD8 核心受体增强 T 细胞受体 (TCR) 对癌症抗原的敏感性. 这种方法可以提高低亲和度TCR的识别,而不会导致不必要的激活,从而有可能改善癌症免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- CD8 T 细胞的识别依赖于 T 细胞受体 (TCR) 和 CD8 核受体与主要基因相容性复合体I类 (pMHCI) 结合.
- 调节对pMHCI的CD8核受体亲和力可以在体外改变抗原识别灵敏度.
研究的目的:
- 为了表征具有增强pMHCI亲和力的CD8变体.
- 评估这些变异是否可以在没有非特异性T细胞激活的情况下提高抗原敏感性.
- 评估增强向癌症的T细胞疗法的治疗潜力.
主要方法:
- 描述了两个CD8变体,对pMHCI有中度增强的亲和力.
- 在模型系统和初级T细胞 (CD4+和CD8+) 中表达的CD8变异.
- 利用向癌症的T细胞受体 (TCR) 来评估功能敏感性和特异性.
主要成果:
- CD8变种优先增强pMHCI抗原识别与低亲缘关系的TCR.
- 在模型系统和具有癌症向TCRs的初级CD4+T细胞中观察到增强的敏感性.
- 高亲和度 CD8 变体改善了原发性 CD8+ T 细胞的功能敏感性,但保留了特异性.
结论:
- 工程 CD8 核受体可以通用地提高低亲和度 pMHCI 抗原识别的灵敏度.
- 这一策略有可能在癌症免疫治疗中增加临床相关的TCRs的治疗疗效.
更多相关视频
08:10Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
Published on: November 28, 2018
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
相关概念视频
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Affinity and Avidity
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
